Analysts Set Eli Lilly and Company (NYSE:LLY) Target Price at $1,218.33

Shares of Eli Lilly and Company (NYSE:LLY) have received a consensus recommendation of “Moderate Buy” from the thirty ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, twenty-three have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $1,218.3333.

A number of research analysts have issued reports on LLY shares. Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Daiwa Securities Group lifted their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. HSBC cut Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their target price for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Wolfe Research reiterated an “outperform” rating and issued a $1,325.00 target price on shares of Eli Lilly and Company in a research report on Monday, May 4th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Liontrust Investment Partners LLP grew its position in Eli Lilly and Company by 46.7% in the first quarter. Liontrust Investment Partners LLP now owns 30,753 shares of the company’s stock valued at $28,286,000 after acquiring an additional 9,788 shares during the last quarter. Leigh Baldwin & CO. LLC boosted its stake in shares of Eli Lilly and Company by 2.3% during the first quarter. Leigh Baldwin & CO. LLC now owns 1,467 shares of the company’s stock valued at $1,349,000 after purchasing an additional 33 shares in the last quarter. TrueWealth Financial Partners boosted its stake in shares of Eli Lilly and Company by 75.6% during the first quarter. TrueWealth Financial Partners now owns 395 shares of the company’s stock valued at $363,000 after purchasing an additional 170 shares in the last quarter. Pathway Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 3.6% during the first quarter. Pathway Wealth Management LLC now owns 7,248 shares of the company’s stock valued at $6,666,000 after purchasing an additional 250 shares in the last quarter. Finally, Western Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 54.6% during the first quarter. Western Wealth Management LLC now owns 13,214 shares of the company’s stock valued at $12,154,000 after purchasing an additional 4,665 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,016.05 on Friday. The company’s 50 day simple moving average is $940.69 and its 200 day simple moving average is $1,002.07. The stock has a market capitalization of $956.85 billion, a price-to-earnings ratio of 36.09, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly said results from its oral GLP-1 program are encouraging, supporting the outlook for a future pill that could broaden the company’s obesity and diabetes franchise. From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
• Positive Sentiment: The company expanded its pipeline with the acquisition of Engage Biologics for up to $202 million, adding non-viral DNA delivery technology and strengthening its genetic medicine ambitions. Eli Lilly Buys Engage Biologics for Up to $202 Million
• Positive Sentiment: Lilly also expanded access to its TuneLab AI/ML drug discovery platform through a partnership with Collaborative Drug Discovery, reinforcing its push to use artificial intelligence to accelerate R&D. Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault
• Positive Sentiment: Analysts and industry coverage highlighted Lilly’s strong earnings call and its high R&D performance, which support the view that the company’s growth trajectory remains strong. Eli Lilly Earnings Call Signals High-Growth Trajectory
• Neutral Sentiment: Lilly completed a large $8.9 billion debt offering, which gives the company additional financial flexibility but also increases leverage. Eli Lilly Raises $8.9 Billion in Debt Offering
• Neutral Sentiment: A lawsuit alleging more than $200 million in Trulicity rebate fraud is a separate risk factor, though it appears to be more about recovering losses than a direct operational setback. Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.